Table 4 Targeted agents in patients with... | American Society of Hematology

Table 4

Targeted agents in patients with MALT lymphoma: single agents and combinations

Agents	Study type	No. of cases	ORR, %	CR, %
Single-agent trials
Abexinostat¹²⁶	Phase 2	13*	15*	0*
Bortezomib¹²⁷	Phase 2	32	48	31
Entospletinib¹²⁸	Phase 2	17*	18*	0*
Everolimus¹²⁹	Phase 2	16	25	6
Ibrutinib¹³⁰	Phase 1	4*	25*	0*
Idelalisib^131,132	Phase 1	3*	0*	0
Idelalisib^131,132	Phase 2	9*	56*	11
Lenalidomide¹³³	Phase 2	18	61	33†
Tazemetostat¹³⁴	Phase 1	1*	100*	n.a.
Thalidomide¹³⁵	Phase 2	8	0‡	0‡
Combination trials
Bortezomib, rituximab¹³⁶	Phase 2	8*	50*	n.a.
Ibrutinib, lenalidomide¹³⁷	Phase 1	2*	50*	0*
Ibrutinib, rituximab, bendamustine¹³⁸	Phase 1	1*	100*	0*
Idelalisib, lenalidomide, rituximab¹³⁹	Phase 1	1*	n.a.§	n.a.§
Lenalidomide, rituximab¹⁴⁰	Phase 2	46	80	54
Lenalidomide, rituximab¹⁴¹	Phase 2	27*	89*	67*
Lenalidomide, rituximab, bendamustine¹⁴²	Phase 1	3*	67*	0*
Venetoclax, bendamustine, rituximab¹⁴³	Phase 1	4*	75*	25*

Agents	Study type	No. of cases	ORR, %	CR, %
Single-agent trials
Abexinostat¹²⁶	Phase 2	13*	15*	0*
Bortezomib¹²⁷	Phase 2	32	48	31
Entospletinib¹²⁸	Phase 2	17*	18*	0*
Everolimus¹²⁹	Phase 2	16	25	6
Ibrutinib¹³⁰	Phase 1	4*	25*	0*
Idelalisib^131,132	Phase 1	3*	0*	0
Idelalisib^131,132	Phase 2	9*	56*	11
Lenalidomide¹³³	Phase 2	18	61	33†
Tazemetostat¹³⁴	Phase 1	1*	100*	n.a.
Thalidomide¹³⁵	Phase 2	8	0‡	0‡
Combination trials
Bortezomib, rituximab¹³⁶	Phase 2	8*	50*	n.a.
Ibrutinib, lenalidomide¹³⁷	Phase 1	2*	50*	0*
Ibrutinib, rituximab, bendamustine¹³⁸	Phase 1	1*	100*	0*
Idelalisib, lenalidomide, rituximab¹³⁹	Phase 1	1*	n.a.§	n.a.§
Lenalidomide, rituximab¹⁴⁰	Phase 2	46	80	54
Lenalidomide, rituximab¹⁴¹	Phase 2	27*	89*	67*
Lenalidomide, rituximab, bendamustine¹⁴²	Phase 1	3*	67*	0*
Venetoclax, bendamustine, rituximab¹⁴³	Phase 1	4*	75*	25*

Data were collected from full papers and from abstracts presented at the 2015 meeting of the American Society of Hematology with results available for MZL patients.

n.a., not available.

Unspecified whether MALT lymphoma, splenic MZL, or nodal MZL.

†

39% CR at a later report.¹⁴⁴

‡

25% ORR, 25% CR at a later report.¹⁴⁴

Trial stopped after 7 lymphoma patients due to hepatotoxicity.

View Large

This Feature Is Available To Subscribers Only